Author
Listed:
- Jialin Xia
(Peking University
Peking University Third Hospital
Peking University
Peking University Third Hospital)
- Hong Chen
(Peking University
Peking University Third Hospital
Peking University
Peking University Third Hospital)
- Xiaoxiao Wang
(Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis)
- Weixuan Chen
(Peking University Third Hospital
Peking University)
- Jun Lin
(Peking University
Peking University Third Hospital
Peking University)
- Feng Xu
(Peking University
Peking University Third Hospital
Peking University)
- Qixing Nie
(Peking University
Peking University Third Hospital
Peking University)
- Chuan Ye
(Peking University
Peking University Third Hospital
Peking University)
- Bitao Zhong
(Peking University)
- Min Zhao
(Peking University Third Hospital
Peking University)
- Chuyu Yun
(Peking University Third Hospital
Peking University)
- Guangyi Zeng
(Peking University
Peking University Third Hospital
Peking University
Peking University Third Hospital)
- Yuejian Mao
(Peking University)
- Yongping Wen
(Mengniu Institute of Nutrition Science)
- Xuguang Zhang
(Mengniu Institute of Nutrition Science
The Chinese Academy of Sciences)
- Sen Yan
(Peking University Third Hospital
Peking University)
- Xuemei Wang
(Peking University
Peking University Third Hospital
Peking University)
- Lulu Sun
(Peking University
Peking University Third Hospital)
- Feng Liu
(Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis)
- Chao Zhong
(Peking University)
- Pengyan Xia
(Peking University)
- Changtao Jiang
(Peking University
Peking University Third Hospital
Peking University
Peking University)
- Huiying Rao
(Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis)
- Yanli Pang
(Peking University
Peking University Third Hospital
Peking University)
Abstract
Non-alcoholic steatohepatitis (NASH) is a severe type of the non-alcoholic fatty liver disease (NAFLD). NASH is a growing global health concern due to its increasing morbidity, lack of well-defined biomarkers and lack of clinically effective treatments. Using metabolomic analysis, the most significantly changed active lipid sphingosine d18:1 [So(d18:1)] is selected from NASH patients. So(d18:1) inhibits macrophage HIF-2α as a direct inhibitor and promotes the inflammatory factors secretion. Male macrophage-specific HIF-2α knockout and overexpression mice verified the protective effect of HIF-2α on NASH progression. Importantly, the HIF-2α stabilizer FG-4592 alleviates liver inflammation and fibrosis in NASH, which indicated that macrophage HIF-2α is a potential drug target for NASH treatment. Overall, this study confirms that So(d18:1) promotes NASH and clarifies that So(d18:1) inhibits the transcriptional activity of HIF-2α in liver macrophages by suppressing the interaction of HIF-2α with ARNT, suggesting that macrophage HIF-2α may be a potential target for the treatment of NASH.
Suggested Citation
Jialin Xia & Hong Chen & Xiaoxiao Wang & Weixuan Chen & Jun Lin & Feng Xu & Qixing Nie & Chuan Ye & Bitao Zhong & Min Zhao & Chuyu Yun & Guangyi Zeng & Yuejian Mao & Yongping Wen & Xuguang Zhang & Sen, 2024.
"Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α,"
Nature Communications, Nature, vol. 15(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48954-2
DOI: 10.1038/s41467-024-48954-2
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48954-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.